Payment overview · 2025
General Payments
$64.85
3 reported records · 2 companies
Healthcare provider profile · identity verified
James Andrew Warr, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOUNTAIN HOME, AR · NPI 1770628471
Verified facts
What the public records show
CMS Open Payments records show James Andrew Warr, MD received $64.85 in general payments during 2025 across 3 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 73.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.44 | 73.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.41 | 26.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $64.85 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.44 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 166 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
166 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 635 | 158 |
| Levothyroxine Sodium | Levothyroxine Sodium | 612 | 141 |
| Lisinopril | Lisinopril | 584 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 553 | 137 |
| Pantoprazole Sodium | Pantoprazole Sodium | 498 | 125 |
| Gabapentin | Gabapentin | 466 | 107 |
| Losartan Potassium | Losartan Potassium | 377 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 372 | 91 |
| Trazodone Hcl | Trazodone Hcl | 344 | 82 |
| Alprazolam | Alprazolam | 332 | 58 |
| Furosemide | Furosemide | 319 | 95 |
| Metformin Hcl | Metformin Hcl | 317 | 85 |
| Ozempic | Semaglutide | 300 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 283 | 92 |
| Allopurinol | Allopurinol | 279 | 63 |
| Omeprazole | Omeprazole | 277 | 72 |
| Glipizide | Glipizide | 265 | 65 |
| Meloxicam | Meloxicam | 261 | 67 |
| Simvastatin | Simvastatin | 256 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 251 | 67 |
| Potassium Chloride | Potassium Chloride | 242 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 219 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 53 |
| Diclofenac Sodium | Diclofenac Sodium | 204 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 188 | 46 |
| Clonazepam | Clonazepam | 187 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 184 | 41 |
| Tramadol Hcl | Tramadol Hcl | 168 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 166 | 35 |
| Propranolol Hcl | Propranolol Hcl | 162 | 41 |
| Topiramate | Topiramate | 161 | 45 |
| Montelukast Sodium | Montelukast Sodium | 146 | 36 |
| Sertraline Hcl | Sertraline Hcl | 143 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 45 |
| Lovastatin | Lovastatin | 133 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 34 |
| Diazepam | Diazepam | 132 | 25 |
| Celecoxib | Celecoxib | 130 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 128 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 124 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 35 |
| Eliquis | Apixaban | 115 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 26 |
| Atenolol | Atenolol | 109 | 27 |
| Aripiprazole | Aripiprazole | 108 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 105 | 28 |
| Lorazepam | Lorazepam | 104 | 21 |
| Finasteride | Finasteride | 102 | 28 |
| Carvedilol | Carvedilol | 99 | 31 |
| Amoxicillin | Amoxicillin | 97 | 80 |
| Azithromycin | Azithromycin | 94 | 75 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 22 |
| Memantine Hcl | Memantine Hcl | 84 | 13 |
| Jardiance | Empagliflozin | 83 | 21 |
| Warfarin Sodium | Warfarin Sodium | 83 | 16 |
| Spironolactone | Spironolactone | 82 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 75 | 20 |
| Ezetimibe | Ezetimibe | 74 | 20 |
| Metformin Hcl Er | Metformin Hcl | 71 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 15 |
| Temazepam | Temazepam | 71 | 11 |
| Alendronate Sodium | Alendronate Sodium | 70 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 69 | 14 |
| Fenofibrate | Fenofibrate | 69 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 59 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | 16 |
| Myrbetriq | Mirabegron | 65 | 16 |
| Clonidine Hcl | Clonidine Hcl | 64 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 15 |
| Nystatin | Nystatin | 62 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 15 |
| Nifedipine Er | Nifedipine | 61 | 14 |
| Bumetanide | Bumetanide | 60 | 20 |
| Bupropion Xl | Bupropion Hcl | 60 | 12 |
| Methylprednisolone | Methylprednisolone | 59 | 50 |
| Famotidine | Famotidine | 58 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 15 |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 56 | 14 |
| Methocarbamol | Methocarbamol | 55 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 43 |
| Pregabalin | Pregabalin | 54 | 14 |
| Estradiol | Estradiol | 53 | 14 |
| Ondansetron Odt | Ondansetron | 50 | 26 |
| Donepezil Hcl | Donepezil Hcl | 47 | 14 |
| Prednisone | Prednisone | 47 | 33 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 11 |
| Baclofen | Baclofen | 43 | 13 |
| Dexamethasone | Dexamethasone | 43 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Ibuprofen | Ibuprofen | 41 | suppressed |
| Carisoprodol | Carisoprodol | 40 | suppressed |
| Gemfibrozil | Gemfibrozil | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 38 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 24 |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 27 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 25 |
| Terbinafine Hcl | Terbinafine Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 14 |
| Fluconazole | Fluconazole | 28 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 19 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 15 |
| Risperidone | Risperidone | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Roflumilast | Roflumilast | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 15 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 12 |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Metaxalone | Metaxalone | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Phentermine Hcl | Phentermine Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $64.85 · 3 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, TRELEGY ELLIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error